Condition: Glioma · Glioma Tumor Recurrence · Glioma, Recurrent High Grade · Sponsor: Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.
This description comes directly from the study's public registry record.
Jianing Wang · 86-13802107048 · wangjianing@buchangbio.com
Xinlei Guo · 0086-10-87163362 · guoxinlei@buchangbio.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06773481